SBFM Sunshine Biopharma (SBFM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001402328
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter
What the filings say about SBFM
Congress, 1 year
No trades
Last one: purchase, 2022-06-30
Sunshine Biopharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Sunshine Biopharma Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 8, 2024.
- The trade is 76.9% of the 130,000 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Slilaty Steve N. bought about $10.0K of SBFM on Mar 4, 2024, the largest insider purchase at the company since 2022; 5 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 66.7% of the 30,000 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Slilaty Steve N. bought about $2.0K of SBFM on Feb 8, 2024, the largest insider purchase at the company since 2022; 5 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 3, 2022.
- The trade is 17.2% of the 174,465 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO/Secretary Sebaaly Camille bought about $22.8K of SBFM on Nov 30, 2022; 5 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 17.3% of the 144,465 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO/Secretary Sebaaly Camille bought about $30.5K of SBFM on Jun 3, 2022, the largest insider purchase at the company on our record; 5 funds added in the latest 13F quarter.4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
+4.1% year over year
more than 51% of Pharma & Biotech
Margin
-16.5% net margin
more than 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
21.7% of shares outstanding short · 1.0 days to cover · settled 2026-10-15
more than 96% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SBFM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-85.7%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SBFM: institutional holders (13F)
13F holdings, latest reported quarter
14,974 sh
$31.4K
385 sh
$808
11,879 sh
$546
162 sh
$340
449 sh
$27
Congress trades in SBFM
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2022-06-30 · disclosed 713 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SBFM planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SBFM financials
Revenue growth
+4.1%
XBRL, annual
Net margin
-16.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$35.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SBFM
| FY Dec 2025 | $36.3M |
| FY Dec 2024 | $34.9M |
| FY Dec 2023 | $24.1M |
| FY Dec 2022 | $4.3M |
| FY Dec 2021 | $228.4K |
| Jun 2026 | $9.3M |
| Mar 2026 | $8.1M |
| Dec 2025 | $8.6M |
| Sep 2025 | $9.4M |
| Jun 2025 | $9.4M |
| Mar 2025 | $8.9M |
| Dec 2024 | $9.6M |
| Sep 2024 | $8.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-16.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SBFM
| FY Dec 2025 | -16.5% |
| FY Dec 2024 | -14.7% |
| FY Dec 2023 | -18.7% |
| FY Dec 2022 | -615.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | -16.9% |
| Mar 2026 | -15.4% |
| Dec 2025 | -25.0% |
| Sep 2025 | -9.4% |
| Jun 2025 | -18.8% |
| Mar 2025 | -13.3% |
| Dec 2024 | -22.5% |
| Sep 2024 | -14.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$5.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SBFM
| FY Dec 2025 | -$5.5M |
| FY Dec 2024 | -$14.2M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$925.0K |
| Mar 2026 | -$2.1M |
| Dec 2025 | -$1.6M |
| Sep 2025 | -$754.7K |
| Jun 2025 | -$1.4M |
| Mar 2025 | -$1.7M |
| Dec 2024 | -$3.5M |
| Sep 2024 | -$1.9M |
At each fiscal year end
Single quarter
Debt to equity
0.07x
long-term debt only, 2021-06-30 (60 months older than the period end); equity 2026-06-30
Debt to equity SBFM
| FY Dec 2025 | 0.09x |
| FY Dec 2024 | 0.09x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | 0.09x |
| FY Dec 2021 | 9.71x |
| Jun 2026 | 0.07x |
| Mar 2026 | 0.10x |
| Dec 2025 | 0.09x |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.08x |
| Mar 2025 | 0.09x |
| Dec 2024 | 0.09x |
| Sep 2024 | 0.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.61x
TTM operating cash flow over long-term debt only, 2021-06-30 (60 months older than the period end)
Cash flow to debt SBFM
| FY Dec 2025 | -2.60x |
| FY Dec 2024 | -6.10x |
| FY Dec 2023 | -4.27x |
| FY Dec 2022 | -2.55x |
| FY Dec 2021 | -0.89x |
| Jun 2026 | -2.61x |
| Mar 2026 | -2.78x |
| Dec 2025 | -2.60x |
| Sep 2025 | -3.47x |
| Jun 2025 | -3.76x |
| Mar 2025 | -5.37x |
| Dec 2024 | -6.10x |
| Sep 2024 | -5.75x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-21.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SBFM
| FY Dec 2025 | -25.7% |
| FY Dec 2024 | -23.0% |
| FY Dec 2023 | -21.0% |
| FY Dec 2022 | -244.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | -21.9% |
| Mar 2026 | -27.3% |
| Dec 2025 | -25.7% |
| Sep 2025 | -24.3% |
| Jun 2025 | -25.6% |
| Mar 2025 | -21.2% |
| Dec 2024 | -23.0% |
| Sep 2024 | -18.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-17.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SBFM
| FY Dec 2025 | -19.7% |
| FY Dec 2024 | -17.7% |
| FY Dec 2023 | -15.9% |
| FY Dec 2022 | -170.1% |
| FY Dec 2021 | -765.7% |
| Jun 2026 | -17.8% |
| Mar 2026 | -21.1% |
| Dec 2025 | -19.7% |
| Sep 2025 | -19.5% |
| Jun 2025 | -20.6% |
| Mar 2025 | -16.5% |
| Dec 2024 | -17.7% |
| Sep 2024 | -14.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SBFM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-21.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SBFM
| FY Dec 2025 | -26.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -221.1% |
| FY Dec 2021 | -231.8% |
| Jun 2026 | -21.6% |
| Mar 2026 | -27.8% |
| Dec 2025 | -26.0% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing SBFM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$7.4M
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term debt only, 2021-06-30 (60 months older than the period end), minus cash 2023-06-30
Enterprise value SBFM
| FY Dec 2025 | $42.7M |
| FY Dec 2024 | $42.3M |
| FY Dec 2023 | $139.7B |
| FY Dec 2022 | $289.1B |
| FY Dec 2021 | n/a |
| Jun 2026 | -$7.2M |
| Mar 2026 | $33.3M |
| Dec 2025 | $42.7M |
| Sep 2025 | $50.2M |
| Jun 2025 | $47.9M |
| Mar 2025 | $34.0M |
| Dec 2024 | $42.3M |
| Sep 2024 | $21.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-52.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield SBFM
| FY Dec 2025 | -9.1% |
| FY Dec 2024 | -23.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -51.1% |
| Mar 2026 | -11.5% |
| Dec 2025 | -9.1% |
| Sep 2025 | -10.9% |
| Jun 2025 | -13.0% |
| Mar 2025 | -24.4% |
| Dec 2024 | -23.6% |
| Sep 2024 | -33.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing SBFM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M |
| EPS (diluted) | n/a | -7.32 | -351.36 | -1.76 |
| Operating cash flow | -$5.3M | -$12.5M | -$8.8M | -$5.2M |
| Cash | n/a | n/a | n/a | $21.8M |
| Buybacks | $0 | $3.1M | $541.1K | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
SBFM Stock Sonar score 5/7 axes
Find similar shapesCompareSBFM ranks highest on profitability (70th percentile) and growth (51st), and lowest on institutional and government (5th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SBFM filings, in plain words
Have members of Congress traded SBFM?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Roger Williams dated 2022-06-30.
Read the full summary
Members of Congress have disclosed trades in SBFM, none in the last year; the latest on record is a purchase by Roger Williams dated 2022-06-30. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
